Ayoub A. Bazzaz
Department of the Basic Science, Faculty of Dentistry, University of Kirkuk, Kirkuk, Iraq
Title: Expression of substance-P in normal and abnormal appendicitis
Biography:
Ayoub Bazzaz has obtained PhD at the age of 30 years from Nottingham University, UK and continued postdoctoral research works for over 10 years at Leeds, Liverpool and Cardiff Universities in the UK. He is one of the founder of Faculty of Medicine of Tikrit University, Iraq and first head of Anatomy department 1988-1991. Has supervised and refereed many MSc and PhD students in Iraq, KSA, Libya and UK and has over 60 published scientific papers in reputed International journals.
Abstract:
Specific histological alteration in appendices was studies using immuno-histochemical technique against Substance-P. Fifty patients aged 3-45 years (21 male and 29 female) admitted Azadi Teaching Hospital with clinical sign and symptoms of appendicitis were involved. Significant differences (p≤0.034) was detected at age 11-30 years of ages with clinical suspected appendicitis in most patients while right iliac fossa pain, vomiting and nausea were predominate clinical symptoms yet non-specific signs of appendicitis. Only 18% of cases were normal (without inflammation) were considered experimental cases. In the experimental group the intensity and location of the substance-P expression either: (+) weak; (++) strong or no expression (negative S-P) strongly were detectable in nerve plexus than in acute inflammation of epithelium and muscularis layers of the appendix while in lamina propria the expression was similar between the two groups. The normal symptomatic appendices were found without inflammation; but with clear substance-P expression. It is concluded that the stronger expression of S-P in normal appendices may confirm the concept of neuro-immuno appendicitis which disproves the negative appendectomy term. Further immunohistochemical studies are in place to explore specific histological alteration associated with the pains using other antibodies i.e. vasoactive intestinal polypeptide (VIP) and GAP-43.